FOR IMMEDIATE RELEASE

Contact:
Rachel L. Johnson
1025 Executive Blvd., Suite 112
Chesapeake, VA 23320
Phone: (757) 436-0333
rjohnson@meladine.com

Meladine™ Receives FDA Marketing Clearance as an Accessory to Hair Removal Lasers to Treat Non-pigmented Hair

Chesapeake, VA—February 14, 2003—Creative Technologies, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing clearance to Meladine™ as an Accessory to Surgical Laser Instruments used for Hair Removal. Meladine is the first product of its kind to effectively enhance the effects of hair removal lasers in treating white, gray and blonde hair.

Meladine is a proprietary melanin enhancer that supplements the natural melanin in hair. A patented liposome delivery system ensures that the pigment is able to penetrate deep into the hair follicle to provide melanin to the bulb and the bulge. The melanin deposit provides a temporary melanin-rich target in the follicle to aid the effects of the laser.

Clearance was granted based on data from a 2 year clinical study. The study included 40 adult patients, aged 28 to 75, suffering from mild to excessive non-pigmented hair growth. Each patient was pretreated with Meladine for 14 days prior to laser hair removal treatment. As a control group, 20 patients with non-pigmented hair growth received laser hair removal treatment without the use of a melanin enhancer.

Results from the study reveal that six months after the last laser treatment, 90% of the patients experienced permanent hair reduction of over 75% within 10 treatments, with an average number of 7 treatments. With an average of 8 treatments, 62.5% of the patients experienced a hair reduction of 95% or more. These results are in contrast to 0% hair reduction experienced by the control group who did not use Meladine.

In addition to FDA clearance, several recent advances have solidified Meladine’s position as an effective method for treating non-pigmented hair. At the annual meeting of the American Society for Dermatologic Surgery in November, Dr. Tina Alster and Dr. Elizabeth Tanzi of the Washington Institute of Dermatologic Laser Surgery released preliminary results from an on-going clinical trial on Meladine. Early results reveal that 1 month after the third laser treatment, 49-54% vellus hair reduction was noted in each patient studied. These results have triggered widespread publicity of Meladine in several highly acclaimed publications such as Dermatology Times, Dermascope, Allure, and Aesthetic Buyers Guide.

“While products in the past have promised the removal of non-pigmented hair, Meladine has demonstrated lasting results time and again.” says President and CEO of Creative Technologies, Inc., Dennis R. Jones. “There isn’t a laser hair removal facility in the world that doesn’t deal with the frustration of treating white, gray and blonde hair—whether is it a patient that must be turned down because their hair is not the right color, or the residual 10% vellus hairs that appear in a patient’s final treatments. We anticipate that FDA clearance will inspire the additional confidence that doctors and laser hair removal facilities need to try Meladine in their practices. Meladine is the safe and effective product that the laser hair removal industry has been waiting for”.

###